verapamil has been researched along with levodopa in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kamal, TJ; Molitch, ME | 1 |
| Andersson, DE; Röjdmark, S; Sundblad, L | 1 |
| Kamal, TJ; Kelley, SR; Molitch, ME | 1 |
| Pestana, M; Serrão, MP; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Gomes, R; Sampaio-Maia, B; Soares-da-Silva, P | 1 |
| Serrão, MP; Soares-Da-Silva, P | 1 |
| Hirose, S; Kaneko, S; Okada, M; Yoshida, S; Zhu, G | 1 |
| Galenko-Yaroshevskii, PA; Kade, AKh; Khvitiya, NG; Kiguradze, MI; Tatulashvili, DR; Turovaya, AY; Uvarov, AE | 1 |
| Babita, K; Tiwary, AK | 1 |
| Andreotti, F; Brouwer, MA; Bukowski, P; Conte, M; Gajda, J; Gajda, R; Jasiewicz, M; Kubica, A; Kubica, J; La Torre, G; Lackowski, P; Michalski, P; Navarese, EP; Nowicka, M; Omyła, M; Orsini, N; Piasecki, M; Pietrzykowski, Ł; Pinkas, J; Podhajski, P; Radziwanowski, A; Szymański, P; Urbanowicz, I | 1 |
1 trial(s) available for verapamil and levodopa
| Article | Year |
|---|---|
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.
Topics: Amiodarone; C-Reactive Protein; Carbidopa; COVID-19; Drug Combinations; Humans; Ion Channels; Levodopa; SARS-CoV-2; Verapamil | 2022 |
19 other study(ies) available for verapamil and levodopa
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine.
Topics: Adult; Bromocriptine; Calcium Channels; Growth Hormone; Humans; Kinetics; Levodopa; Male; Middle Aged; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Time Factors; Verapamil | 1992 |
Calcium and calcium-antagonistic effects on prolactin and growth hormone responses to thyrotropin-releasing hormone and L-dopa in man.
Topics: Adult; Calcium; Female; Growth Hormone; Humans; Kinetics; Levodopa; Prolactin; Reference Values; Thyrotropin-Releasing Hormone; Verapamil | 1981 |
Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
Topics: Adolescent; Adult; Calcium Channel Blockers; Carbidopa; Dopamine; Female; Humans; Hyperprolactinemia; Levodopa; Male; Middle Aged; Prolactin; Verapamil | 1996 |
Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benserazide; Body Water; Calcium Channel Blockers; Cell Survival; Cyclosporine; Decarboxylation; Dopamine; Dopamine Agents; Levodopa; LLC-PK1 Cells; Swine; Verapamil | 1998 |
P-glycoprotein phosphorylation/dephosphorylation and cellular accumulation of L-DOPA in LLC-GA5 Col300 cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; Humans; Kidney; Levodopa; Okadaic Acid; Phorbols; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Kinase C; Staurosporine; Time Factors; Verapamil | 1999 |
Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Line; Dopamine; Fluoresceins; Fluorescent Dyes; Humans; Kidney; Kinetics; Levodopa; LLC-PK1 Cells; Proteins; Rhodamine 123; Swine; Verapamil; Vinblastine | 2000 |
Both 3,4-dihydroxyphenylalanine and dopamine releases are regulated by Ca2+-induced Ca2+ releasing system in rat striatum.
Topics: Adenosine; Analysis of Variance; Animals; Calcium; Calcium Channels; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Electrochemistry; Inositol 1,4,5-Trisphosphate; Inositol 1,4,5-Trisphosphate Receptors; Levodopa; Macrocyclic Compounds; Male; Microdialysis; Oxazoles; Potassium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Ruthenium Red; Ryanodine; Ryanodine Receptor Calcium Release Channel; Time Factors; Verapamil | 2004 |
Effects of verapamil and amiodarone on sympathoadrenal system and balance of excitatory and inhibitory amino acids in rat medulla oblongata.
Topics: Adrenal Glands; Amiodarone; Animals; Calcium Channel Blockers; Dopamine; Epinephrine; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Levodopa; Male; Medulla Oblongata; Microinjections; Norepinephrine; Potassium Channel Blockers; Random Allocation; Rats; Rats, Inbred Strains; Serotonin; Sympathetic Nervous System; Verapamil | 2005 |
Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa.
Topics: Administration, Cutaneous; Animals; Anticholesteremic Agents; Antiparkinson Agents; Atorvastatin; beta-Alanine; Calcium Channel Blockers; Calcium Chloride; Cholesterol; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; In Vitro Techniques; Levodopa; Male; Pyrroles; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Sphingosine; Time Factors; Verapamil | 2004 |